FDA Brief

Warning letters Drugs

FDA warning letter to

Cipla Limited

High riskIssued Nov 17, 2023Posted Nov 21, 2023Center for Drug Evaluation and Research | CDER

FDA warned Cipla about unresolved albuterol inhaler delivery complaints and contamination in sterile manufacturing at its Indore site.

What happened

FDA inspected Cipla’s Indore, India, drug manufacturing facility from February 6 to February 17, 2023. It found inadequate investigations of about 3,000 Albuterol Sulfate Inhalation Aerosol complaints from April 2020 to December 2022 and about 2,000 more from January to August 2023, a failure to submit a Field Alert Report, contamination in sterile-process simulation runs with gram-negative microbes, environmental monitoring problems, and bags of scrap containing manufacturing records with Quality Assurance signatures. FDA said Cipla’s March 10, 2023 response was inadequate.

What FDA found

  1. Cipla did not thoroughly investigate albuterol inhaler complaints or extend investigations to other potentially affected batches, and its corrective and preventive actions were inadequate.

    21 CFR 211.192
  2. Cipla did not submit a Field Alert Report to FDA within three working days after learning of significant product deterioration or change in a distributed drug product.

    section 505(k) of the FD&C Act; 21 CFR 314.81(b)(1)(ii)
  3. Cipla did not establish or follow adequate written procedures to prevent microbiological contamination of sterile drug products, including validation of aseptic and sterilization processes.

    21 CFR 211.113(b)
  4. Cipla’s quality unit did not adequately oversee retention of current good manufacturing practice (CGMP) records, and original records were found in scrap intended for shredding.

    21 CFR 211.22(d)

What FDA wants

FDA asks Cipla to provide independent assessments, remediation plans, retrospective reviews, risk assessments, and management strategies for its complaint, investigation, aseptic, environmental monitoring, and record systems. The letter text provided does not state a response deadline.

Who should pay attention

  • patients and clinicians who rely on albuterol rescue inhalers
  • companies that buy or distribute Cipla-made inhalers or sterile drugs
  • quality and manufacturing teams at sterile drug facilities

This is a summary. Read the original letter on fda.gov.

Cipla Limited's FDA history

Recalls in the last 12 months

Dec 10, 2025 Class II Cipla Limited
Drug
Phytonadione Injectable Emulsion, USP 10mg/mL, 10x1 mL Single-Dose Vial/carton, Rx Only, Mfd. by: Cipla Ltd. India At M/s Immacule Lifesciences PVT. Ltd. India. Mfd. for: Cipla USA, Inc. Warren, NJ 07059. Vial NDC# 69097…
Failed Stability Specifications: Observed OOS results: eg results for colour index

Full company page

Similar letters to other companies

  1. Conroe Welding Supply, Inc.

    FDA warns Conroe Welding Supply over medical oxygen manufacturing failures, including untested batches and a container with 99% (b)(4).

    High risk
  2. Peter Schiff Enterprises

    FDA warns Peter Schiff Enterprises over unapproved cardiac devices and serious quality system failures.

    High risk
  3. Chirp Innovations, LLC

    FDA warned Chirp Innovations over quality-system gaps, missing adverse-event reporting procedures, and unapproved marketing of its Halo muscle stimulator for menstrual pain.

    High risk
  4. Rohto Pharmaceutical Co., Ltd.

    FDA cites Rohto Vietnam eye-drop plant for falsified sterility records, poor aseptic practices, and unapproved Cooling Eye Drops.

    High risk